SQZ Biotechnologies Company
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment o… Read more
SQZ Biotechnologies Company (SQZB) - Total Assets
Latest total assets as of September 2023: $29.79 Million USD
Based on the latest financial reports, SQZ Biotechnologies Company (SQZB) holds total assets worth $29.79 Million USD as of September 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
SQZ Biotechnologies Company - Total Assets Trend (2018–2022)
This chart illustrates how SQZ Biotechnologies Company’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
SQZ Biotechnologies Company - Asset Composition Analysis
Current Asset Composition (December 2022)
SQZ Biotechnologies Company's total assets of $29.79 Million consist of 63.6% current assets and 36.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 59.4% |
| Accounts Receivable | $384.00K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $29.39 Million | 27.4% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2022)
This chart illustrates how SQZ Biotechnologies Company's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SQZ Biotechnologies Company's current assets represent 63.6% of total assets in 2022, a decrease from 94.2% in 2018.
- Cash Position: Cash and equivalents constituted 59.4% of total assets in 2022, up from 51.6% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is property, plant & equipment at 27.4% of total assets.
SQZ Biotechnologies Company Competitors by Total Assets
Key competitors of SQZ Biotechnologies Company based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
SQZ Biotechnologies Company - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - SQZ Biotechnologies Company generates 0.20x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - SQZ Biotechnologies Company is currently not profitable relative to its asset base.
SQZ Biotechnologies Company - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.37 | 3.46 | 4.25 |
| Quick Ratio | 1.37 | 3.46 | 4.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.25 Million | $ 62.08 Million | $ 127.06 Million |
SQZ Biotechnologies Company - Advanced Valuation Insights
This section examines the relationship between SQZ Biotechnologies Company's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.38 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -52.6% |
| Total Assets | $107.19 Million |
| Market Capitalization | $707.79K USD |
Valuation Analysis
Below Book Valuation: The market values SQZ Biotechnologies Company's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: SQZ Biotechnologies Company's assets decreased by 52.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for SQZ Biotechnologies Company (2018–2022)
The table below shows the annual total assets of SQZ Biotechnologies Company from 2018 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | $107.19 Million | -52.60% |
| 2021-12-31 | $226.15 Million | -2.16% |
| 2020-12-31 | $231.14 Million | +51.72% |
| 2019-12-31 | $152.35 Million | +31.85% |
| 2018-12-31 | $115.55 Million | -- |